Library 54 Administrative Branch 4 57

REPORT NO. 273 DECEMBER 21, 1962

COMMUNICABLE DISEASE CENTER

SURVEILANCE

TABLE OF CONTENTS

SUMMARY


- I. CURRENT MORBIDITY TRENDS
- **II. STATE REPORTS**
- III. 1962 CASES REPORTED TO PSU
- IV. ROUTINE SURVEILLANCE 1962

SUPPLEMENT TO PSU REPORT 273

NEWS RELEASE FOLLOWING SURGEON GENERAL'S O.P.V. ADVISORY COMMITTEE MEETING DECEMBER 17, 1962

CASES CONSIDERED BY COMMITTEE

U. S. DEPARTMENT OF HEALTH, EDUCATION, AND WELFARE PUBLIC HEALTH SERVICE





PREFACE

Summarized in this report is information received from State Health Departments, university investigators, virology laboratories and other pertinent sources, domestic and foreign. Much of the information is preliminary. It is intended primarily for the use of those with responsibility for disease control activities. Anyone desiring to quote this report should contact the original investigator for confirmation and interpretation.

Contributions to the Surveillance Report are most welcome. Please address to: Chief, Poliomyelitis Surveillance Unit, Communicable Disease Center, Atlanta 22, Georgia.

Communicable Disease Center

Epidemiology Branch

Statistics Section Surveillance Section

Poliomyelitis Surveillance Unit

James L. Goddard, M.D., Chief

Alexander D. Langmuir, M.D., Chief

Admint Stratt ve Branch

Robert E. Serfling, Ph.D., Chief Donald A. Henderson, M.D., Chief

James A. Bryan, II, M.D., Chief John J. Witte, M.D. Saul Rosenberg, Statistician

SUMMARY

The three weeks which ended on December 15, 1962 brought reports of 36 cases of poliomyelitis, 31 paralytic. Only 6 cases, 5 paralytic, were reported for the last of those weeks.

No new case concentrations have been noted. A report on Oklahoma whose 1962 experience with poliomyelitis has greatly exceeded that in 1961 is presented in Section 2.

Individual case forms have been received on 584 of the 664 paralytic cases with onset in 1962. An analysis by age and vaccination status reveals that 80% of cases occurred in persons younger than 15 years of age with over 60% of these being unvaccinated. This material is shown in Section 3.

The result of the deliberations of the Surgeon General's Advisory Committee which considered the occurrence of paralytic illness among recipients of oral polio vaccine is presented as a supplement to this report. This Committee met on December 17 and 18 in Washington, D.C.

1. CURRENT POLIOMYELITIS MORBIDITY TRENDS

A total of 36 cases of poliomyelitis, 31 paralytic were reported for the three week period which ended December 15, 1962. The last two weeks accounted for only 11 paralytic cases.

Only 18 States reported cases during this time with no new case concentrations being noted. Only California, Indiana and Oklahoma noted as many as three cases. Many of the remaining States noted delayed reports.

As shown in the tabulation below, the cumulative totals for this year remain well below those for 1961, the previous record low year. The six-weeks totals show that the paralytic cases noted during this year slightly exceed the number noted in 1961, while the total number still remains below. Comparable totals for 1962 and the preceding four years are shown below:

Polio	(Cumulated	Weekly)	through	the 50th	Week for	the Past	Five Years
	0.00	1962	1961	1960	1959 <u>1959</u>	<u>1958</u>	23250
	Paralytic			2240	5624	3071	
	Total	860	1321	3210	8448	5958	
Six-W	leek Totals	(45th th)	ough 50t	h Week) i	for Past H		<u>s</u> auā —
	of the parts	1962	<u>1961</u>	1960	<u>1959</u>	1958	ssu tiv
	Paralytic	99	95	243	580	486	
	Total	124	141	324	777	7,58	

2. STATE REPORTS

Thus far in 1962, Oklahoma has reported 32 cases of poliomyelitis, while during the comparable period in 1961 only 4 cases were noted. Of these cases 15 were noted in the north eastern portion of the State in the adjoining counties of Tulsa, Creek, Washington and Muskogee. Tulsa County accounted for 8 cases (6 paralytic). The first case noted in this area had onset in early August while the remaining cases occurred after mid-September. Type I poliovirus was recovered from two of the cases which occurred in Oakhurst (Tulsa County) and Type I polio vaccine was administered in this community in November. No new cases have been reported since that time from any of the four counties.

 autata nortanizzav bno ega gd sizylana nA .5301 Hi testo nitt sezao iu szevezi nadi zaganov encered ni borruzzo sezaz iz 308 zhiz kevez 3. m1962 PARALYTIC CASES REPORTED TO PSU gnise esadi ic 300 revo ditt ega it Scation 3.

Of the 685 cases of paralytic poliomyelitis reported through the week ending December 15, 664 had onset in 1962. The Poliomyelitis Surveillance Unit has received individual case forms on 584 of the 664 paralytic cases. The vaccination status of these 584 paralytic cases by age groups is shown below.

Paralytic Poliomyelitis by Age Group MOLOS TATADO

						n PSU Form	
esposition estriction	C PIDY QU CE MAR	242 (1nr 6361	ougn 1	ecember	15, 1962	y posau uc	A cotal of for the three wee
Age	1 a 4 a 4 a 4 a 4 a 4 a 4 a 4 a 4 a 4 a			85850 0	parelyci	or only li	weeks accounted
Group	ov	1-2V		<u>4+v</u>	Unk	Total	Percent
\$8\$\$0 WS	er en dat	w smil	2113	galich	ted cases	togal reput	only IS St
0-4:17 5mc	196	47	12 6	101711	00 11 0a	. bo 283 gri	48.4 3109000
. aur 5+9 1 baya	54	171	20	27	ारु रह ि ६७०	al 121 Ha	20.7
10-14	23	12		7	2		
15-19 icl	14	svi 31	emm 5 e	rit grof	lati o n be	udad 25 ¹² 5	1 avora 3A
20-29	35	097 788	otvišru	6.14 .1	e *or 196	sont 50 Lad	year remains well
30-39 V	19 tot	ind 4nd	see ac	so z idy	the paral	27	aisio4 6 Hoow-xla
40+	9 0 mm 14 8	100 1 95	: e 0 °d	2 91	ni h olon	ladi l8 1 ad	sityhtly <mark>f:8</mark> eed t rewatus <mark>oelow.</mark> C
TOTAL	355	91	57	62	19	584	100.0
PERCENT	9 all to	i deovi	50ch	olit d <u>au</u>	arda (ylu	osk betalt	Porte (Com
DOSES	62.8	16.1	10.1	11.0	-	100.0	

Of the 272 cases with known vaccination history in the 0-4 age group, 196 (72.1 percent) had not received any poliomyelitis vaccinations.

To date in 1962, the Poliomyelitis Surveillance Unit has received results of virological studies on 356 of the 584 paralytic cases. A total of 305 poliovirus isolates (85.6 percent) has been recovered from the 356 cases. Of these, 233 are Type I, 5 are Type II, and 67 are Type III polioviruses. Isolates associated with clinical paralytic poliomyelitis have been reported from the following States:

TAMMUS

			1401	Poliovin	rus	A service and markets a
	State		I	II	III	Total
	Alabama		6	0	0	6
	Arizona		2	0	0	2
	Arkansas		7	1	0	nyan ing ing pangalan ing pangalan kan sa
	California		20	1	7	28
	Colorado		1	2	0	3
	D.C.	ante pal	0	0	1	en en teatro sera sera se providente de la constante de la constant
	Georgia		5	0	1	6
	Idaho		0	Ō	ī	the second strain is a second strain the second strain second strain strain second strain second strain strain second strain sec
	Illinois		22	0	7	29
	Indiana		6	Õ	ò	23 6 - Maria 10
	Kentucky		10	0	. e e io i . 1	d of includes of the subsystem of the second state second
	Louisiana		11	Õ	6	17
	Maryland		1	Ō	Õ	the second and the second second
	Massachusetts		3	Ō	õ	en alternation 3 en la constante
	Michigan		8	0	4	12
	Minnesota		4	0	0	
	Mississippi		0	0	7	- 12 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1
	Missouri		1	1	0	2
1.000	Montana		1	0	0	the fractional sectors from the sector
3.51.3	Nebraska		0	0	1	ran shall san ta sh
	New Hampshire	ann aith a Cleanaith a	1	0	2	u ante - Entret a far an eg Alt. A de la Alt 3 and a chier been
	New York		6	0	5	11
	North Carolina		2	0	0	2
	Ohio		9	0	4	13
	Oregon		0	0	3	3
	Pennsylvania		5	0	4	e de la contra de la 9
	South Carolina		1	0	2	3
	Tennessee		3	0	2	5
	Texas		83	0	7	90
	Utah	zy k his	1	0	0	and l owers and
	Washington		3	0	1	to the 4 operation present
	West Virginia		9	0	1	10
	Wisconsin		1	0	0	1
	Wyoming		_1	0	0	1
	TOTAL		233	5	67	305
				•	36	

-3-

4. ROUTINE POLIOMYELITIS SURVEILLANCE - 1962

A. Cases with Onset within 30 Days of Vaccine (Inactivated)

1398

One case of poliomyelitis occurring within 30 days following vaccination has been reported by individual surveillance form to the Poliomyelitis Surveillance Unit during the three-week period ending December 15. This patient, a 12 year old male from Presque Isle County, Michigan, was vaccinated on September 12 and had onset of illness on September 28. He previously had received one dose of inactivated vaccine. The preliminary diagnosis was paralytic poliomyelitis. There was no correlation between site of injection and site of first paralysis.

To date in 1962, the Poliomyelitis Surveillance Unit has received reports of 19 cases of poliomyelitis (14 paralytic) occurring within 30 days following vaccination. One paralytic case showed a correlation between site of injection and site of first paralysis. (Note: The 4 year old male from Winnebago County, Illinois, which was listed in PSU Report No. 271, was erroneously repeated in PSU Report No. 272.)

B. Cases with Onset within 30 Days of Vaccine (Oral)

During the three-week period ending December 15, there were 3 cases of poliomyelitis, 1 paralytic, occurring within 30 days following oral vaccination, reported to the Poliomyelitis Surveillance Unit on individual case forms. One was from Massachusetts and two were from Texas. The 54 year-old female from Suffolk County, Massachusetts, had received Type III oral polio vaccine on June 13 and had onset of illness on July 5. No virus isolation was made in this case. Type I oral polio vaccine was administered to the patients from Texas within 30 days prior to onset. All cases represent delayed reports.

A detailed line listing of the 3 cases appears below:

State	County Age Se	<u>Onset</u>			Onset Interval	Doses Paralytic <u>IPV Status</u>
Mass.	Suffolk 54 F	7-5	6-13	III	22 days	0 P .00
Texas	Lubbock 21 F	9-12	8-26	IĈ	17 days	7 matsus NP
Texas	Lynn 16 M	9-10	8-20	I	21 days	l Unk

Sixty-one cases of poliomyelitis, 53 paralytic, occurring within 30 days following oral vaccination have been submitted to the Poliomyelitis Surveillance Unit so far in 1962. The 17 month-old male from Mobile County, Alabama, presented in PSU Report No. 270, has been withdrawn by the State Health Department as not representing poliomyelitis and has been deleted from the 1962 poliomyelitis records.

C. <u>Poliomyelitis within 60 Days Among Household Contacts of</u> Oral Vaccinees

During the three-week period ending December 15, no cases of poliomyelitis occurring within 60 days following oral vaccination among household contacts of oral vaccinees were reported to the Poliomyelitis Surveillance Unit. The total remains at 9 cases, all paralytic, reported in 1962.

C. Poliomvelitis vishin 50 larks Among Hourshold Contains of Oral Pachaese and in the second result.

Ducies the three-week period anding December 13, as cases of policingelitis occurring within 60 days following real vaccination and of correlate contacts of oust vacciness were beported to the Policingelitie formelifance Units. The total remains at 9 cases, all paralytics reported in 1962:

Figure 1

CURRENT U.S. POLIO INCIDENCE COMPARED WITH YEARS 1957, 1959 and 1961 April-December, by week

DATA PROVIDED BY NATIONAL OFFICE OF VITAL STATISTICS AND COMMUNICABLE DISEASE CENTER




Table 1

TREND OF 1962 POLIOMYELITIS INCIDENCE

State and	Cumula tive	-		s Repo				Six		rable	
		11/10		or Wee			70/76	Week		Total	<u>s in</u> 1959
Region	1962	11/10	11/17	11/24	12/1	12/8	12/15	Total	1961	1960	1955
UNITED STATES											
Paralytic	685	30	17	21	20	6	5	99	95	243	580
Nonparalytic	122	5	3	4	1	2	1	16	24	46	131
Unspecified	53	4	1	3	1	-	-	9	22	35	66
Total	860	39	21	28	22	8	6	124	141	324	777
NEW ENGLAND											
Paralytic	8	_	-	1	_	-	-	1	8	16	34
Total	9	1	-	ī	_	-	-	$\overline{2}$	14	18	47
Maine	_	_	-	-		-	-	-	2	10	14
New Hampshire	-	-	-	-	-	-	-	-	_	-	j.
Vermont	1	1	-	-	-	_	-	1	5	2	6
Massachusetts	7	_	-	1	-	-	_	ī	7	5	17
Rhode Island	_	-		_	-		-	_	•	ĩ	_
Connecticut	1	-	-	-	-	-	-	-	-	-	10
MIDDLE ATLANTIC											
Paralytic	60	-	2	- 1	4	-	1	8	22	44	86
Total	81	-	3	1	4	_	1	9	36	58	116
New York	58	-	1	1	1		ĩ	4	30	28	79
New Jersey	9	-	-	_	2	-	-	2	_	4	8
Pennsylvania	14		2	·	1	-	- 1	3	6	26	29
EAST NORTH CENTR	AL										
Paralytic	102	8	3	5	2	3	1	22	21	49	77
Total	135	10	3	6	3	3	ī	26	31	64	120
Ohio	20	_	_	ា	_	-	-	1	5	15	20
Indiana	23	2	-	_	1	2	-	5	3	24	12
Illinois	59	5	3	2	ĩ		_	11	5	14	44
Michigan	21	2	~ <u> </u>	ī	_	1		4	13	5	31
Wisconsin	12	\ī_	_ \	2	1	-	1	5	5	6	13
WEST NORTH CENTR	AL										
Paralytic	27	-	-	-	1-	· -	<u>k</u> \	- 4	6	6	55
Total	38	-	_	-	-	_		/ <u>^_</u>	11	11	81
Minnesota	7	_ '	-	-	_				-	2	19
Iowa	7	-	-	-	_	_		1 1	3	2	23
Missouri	10	_	_	-	-	_			4	3	31
North Dakota	10 5	_	_	_	_	-	_	_	i	2	3
South Dakota	1	_	-	_	-		-	-	3	1	3
Nebraska	8		-	-	~	-	-	-	3	1	2
Kansas	0	-	-	-	-	-	~	-		1	3

Table :	1 (Continued)
---------	-----	------------

<u></u>	Cumula		Cases	Ponet	ad to	CDC		Six	Compa	nahla	Siv
State and	tive		Cases I For	Week 1	eu to Ending			Week	Weeks	Total	sin
Region	1962	11/10	$\frac{101}{17}$	11/24	12/1	12/8	12/15			1960	1959
SOUTH ATLANTIC											
Paralytic	69	6	2	4	3	1	-	16	14	54	99
Total	77	9	2	4	3	1	-	19	15	66	122
Delaware	-	-	-			-	-	-	-	-	-
Maryland	2	1	-	-	-	-	-	1	5	12	6
D.C.	2	-	-		-	~	-	-	-	-	-
Virginia	10	-	-	-	-	1	-	1	1	18	18
West Virginia	18	4	2	3	3	-	-	12	2	?	17
North Carolina	13	2	-		-	~	-	2	5	11	36
South Carolina	6	~	-		-	-	-	-	1	6	10
Georgia	17	2	-	1			-	3	-	6	20
Florida	9	+	-	-	-	-	-	-	6	6	15
EAST SOUTH CENTRAL								_			
Paralytic	67	3	-	6	3		-	12	3	18	66
Total	80	3	-	7	3	-	-	13	4	30	83
Kentucky	29	3	-	-	-	~	-	3	-	10	19
Tennessee	12		-	1	1		-	2	-	11	40
Alabama	22	-	-	-	-		-		1	2	11
Mississippi	17	-	-	6	2	-		8	3	7	13
WEST SOUTH CENTRAL											
Paralytic	254	6	6	3	6	~	3	24	11	24	36
Total	330	8	9	8	6	-	4	35	13	27	47
Arkansas	23	5	3	_	1	-	_	9	4	4	13
Louisiana	30	1	-		3	-	2	6	5	2	11
Oklahoma	32	-	2	6	2	_	1	11	-	-	12
Texas	245	2	4	2	-	-	1	9	4	21	11
MOUNTAIN											
Paralytic	15	4		_	1		_	5	5	7	11
Total	19	4	-	-	1 1	_	-	5	7	17	21
Montana	4		-	-	_		-	_	-	3	3
Idaho	2	-	-	-		-	-	-	-	2	2
Wyoming	2 2	-	-	-	-	-	-		1	3	-
Colorado	4	1	-	-	1		-	2	3	2	1
New Mexico	2	2	-	-	-	-	-	2 2	3 3	2	3
Arizona	4	1		-		-	-	1		4	9
Utah	1		-	-	-		-	-	-	1	1 3 9 2 1
Nevada	-	-	-	-	-	-	-	-	-	-	1
PACIFIC											
Paralytic	83	3	4	1	1	2	-	11	5	25	116
Total	91	4	4	ĩ	2	4	-	15	10	33	140
Washington	5	_	-	_	-	_		-	6	6	24
Oregon	7	1	_	-	1	-	-	2	_	2	30
California	79	3	4	1	1	4	-	13	4	24	77
Alaska	-	-	_	-	_	_			-	_	9
Hawaii	_	-	-	-	~	-		-	-	1	-
TERRITORY											
Puerto Rico	12	-	_	_	·	_		-	-	18	4
ANT ON WIND	<i>12</i>	-	_		-	_				20	

Table 1 (Centinued)

93878 D16	Gumula- tive	ensederation of the source of	Cases R	sporte	d to Inding	9(2)	f and no sector (Six Veck	(sapa) Veelrs	i eldan Totali	Six s in
noizof		AR FE	an alla companya ana ang 1911 - Carlo Ca 1911 - Carlo Car	10/11	TY OF	25.07	SELER	Lator	1001	1960	1.959
1101793	7.0.06	WI YII	MINEL.	67177	17/01	. S. And	Gel Atta	189.04	ALC: L	QUIC 1	CCC1.
SOUTH ATEANTIC											
Sandy Land	63	a	2	N.				16	4.[54	66
isjol	22	0 ()		2 2	् ह	J.		51	1	99	58.L
Delaware					0	ιĨ.		V).			
STERMAN LONG		1	-4	4.40	-		~~~~	Ĩ.		an. An 12	
Maryland D.G.	2			1	1,101	1444	tang			S.L	9
1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1	S.	- 18	14.0	-5.4		-164		**** 2*	- ++ E^4		
shight	0.1		**		**	24	##**	1	Lond,	1.8	1.8
West Virginia	2.8	\$	2.	2	<u>6</u>	-11	1-44	12		1	17
North Carolin	E.C.	2		···•	×4,	- 2-18	***	2		11	38
South Carolina	â	6		• •		1-00-		#1)-1	÷	0	10
n.235060	ter, and	2	24.	and a	444			4.n.*	tari s	0	2.0
Florida	E	-9.9	194		3	194	5421	*		9	1.5
The common original											
LAST SOUTH OLA TAL	53	3	197	3	3			3.2	E	8.5	66
Paralytic	08	5		1	с С			E.I.	т. К.	04. 08 -	83
Total							- 14-1				
Volution	29 29	£		 P	-4 1 ¹⁰	11-12		5	5.9	10	01
tessee.	3.2	191-1		L	Ĩ	141.1	£ 54	1 and 1		and a second	40
smadsIA	22	às A.			254	Ser. S	17.754	atra a	-	ŝ	I.I.
toplastsaff	11	- e %e	×2.,	ð	2		**	8	(A)	200	E.
interne annual annual											
WEST SOUTH CONTRALL		~									
singlenes	254	ð	9		è.		E		££	24	3E
listof	. J3G	8	Ç.	8	ð	~~	Ì.	35	1.3	Star C	2 <u>1</u>
esensial	23	5.87	3	y-tae	£	- 18		6	10	\$	13
Louisiana	36	1 des	***	-	3	Mar.		9	E.	2	1 may
Smoda LiiQ	32	-18	2 5	6	52	100		1.1	1.14	1	SEC
2.53.91	245	₹ <mark>2</mark> 9 tale		2		-	5	Ę.	ę.	22.	1.5
- All											
MULTARIA											
Paralytic	1.5		·•		1		- 14	1	5	Z_{ℓ}	11
Lator	<u>er</u>	4	e la	14.0	1	1,000		5	7	SI	5
enernoù	2	le-spt	· · ·	-1.45		-				3	3
. ogistal.	2		5	+14				~~*	- 10.7	5	2
Primovil		-				1.14-		• ***	. <u>K</u>	3	
oharaloo	ð,		194	***	1 C		~	2	ž.	2	1.
caiseM wow	S.	<u>C</u>	104.4		1944	12.0-0	~ 14		8		8
APRIL 2003	4.	Ĩ	***	*) -			-	1		4	9
1600	Ţ.	ALC: N	1.041			14. A		·	44-2	£	2
1979A		12.49		NO7	1 × 1 m	1.00	- 4			Q-1	1
											402
OTALDAY											
Paralytic	83	3	\$5.	f.		8		25	5	25	115
Istol	100 100	Ň	5	all a	0	1		2.5	01	εĒ.	045
aciantiast	ê.			24	1.5			a salar	6	8	45
10457Q	5 7 2	hear of		4,000	5	14.5		2			-08
Ein cliff	29		104 2	2	L.			а 13	d.	4.5 ···	22
Siesla					da	40 40		C-5.			11
Lista II	49		2.44			8-14		2.04	-		
L.L.B.W.	1-14 ···	and the		A						á.	
THOTTERN											
oolfi ofuse	SE									1.8	22
12-22-22 S. F. F. K. M. S.											

 Statement Released to the Press by the Different Via Stateman Orieral

> SUPPLEMENT TO PSU 273 December 21, 1962

adaamat geleen alkoks kuidu opul kuuuna adtii kumaoon kuuakul lohine L

Special String Isid thet this is the recommendation of the Surgeon Control's Special Advisory Constitute on Grain Deckonymistur Vaciae which concluded its fifth monthly bids year on Decaster II. and that he has recepted the Constitution recommendations,

The Constitutes spressed that openial attraction to given to children because ther comprise the perturbility areas for under the danger of naturally coordering politicity is present and who arrive as the natural source of

A. Statement Released from the Office of the Surgeon General, December 19, 1962.

B. Report of the Special Advisory Committee on Oral Poliomyelitis Vaccine to the Surgeon General.

December 18, 1962

C. Line Listing of Cases Considered by the Committee.

- Dr. -etry president and transfort menting at which construme realized needer as a constant of the transfort pathon that if the st summand is the constant of the realized when whether the class of control which the transform of a transformer to some contenties and sets.

Mi this will and the Sale vertices well average at this had measure applies you and a cont. I believe, book forward to the day when which is then. Lieberated an air some "automatic the bound of the day when with a t of all is and for conset and the transformer to all of a at another and for conset and the second with a at another to be a second of the second of the A. Statement Released to the Press by the Office of the Surgeon General

Communities planning immunization campaigns against poliomyelitis are urged to move ahead, using all three types of Sabin oral vaccine with particular emphasis on children and young adults, Surgeon General Luther L. Terry of the Public Health Service announced today.

Dr. Terry said that this is the recommendation of the Surgeon General's Special Advisory Committee on Oral Poliomyelitis Vaccine which concluded its fifth meeting this year on December 18, and that he has accepted the Committee's recommendations.

The Committee stressed that special attention be given to children because they comprise the population group "in whom the danger of naturally occurring poliomyelitis is greatest and who serve as the natural source of poliomyelitis infection in the community."

A. Statement Released from the Office of the

"The Committee feels and I wholeheartedly agree that of greatest importance is planning for the continuing vaccination of oncoming generations," the Surgeon General said. "This is the only way we will succeed in eradicating polio permanently."

L Report of the Special editions formations on

The Surgeon General quoted the recommendation of the Committee with respect to vaccinations among adults:

"Because the need for immunization diminishes with advancing age and because potential risks of vaccine are believed by some to exist in adults, especially above the age of 30, vaccination should be used for adults only with the full recognition of its very small risk. Vaccination is especially recommended for those adults who are at higher risk of naturally occurring disease; for example, parents of young children, pregnant women, persons in epidemic situations and those planning foreign travel."

Dr. Terry presided at the two-day meeting at which committee members reviewed all cases of suspected polio-like illness currently known to have been associated with the administration of oral polio virus vaccine of all three types in non-epidemic areas.

"In the oral and the Salk vaccines we have two established weapons against polio and we can, I believe, look forward to the day when polio is finally eliminated in this country," the Surgeon General stated. "With a total of around 650 cases reported this year, compared to almost 58,000 a decade ago, it is clear we are well on our way." The total number of cares wavelated with the administration of Type I vacaing and analitered as wooden is seven of which 4 are

In commenting on the work of his Advisory Committee, Dr. Terry said: "The meticulous care with which members of this committee--all experts in the scientific disciplines involved in the use of vaccines--have watched and evaluated developments in the widespread use of oral poliomyelitis vaccines is exemplary." They are rendering an invaluable service in advising us.

Members of the Surgeon General's Committee are: Dr. David Bodian, The Johns Hopkins School of Medicine; Dr. John Fox, Public Health Research Institute of the City of New York; Dr. Archie L. Gray, Secretary and Executive Officer, Mississippi State Board of Health; Dr. William MCD. Hammon, University of Pittsburgh: Dr. Hugh Hussey, Dean, School of Medicine, Georgetown University; Dr. Alexander Langmuir, Public Health Service, Communicable Disease Center, Atlanta, Georgia; Dr. Roderick Murray, Public Health Service, National Institutes of Health, Bethesda, MD; Dr. John Paul, Yale University School of Medicine; Dr. Albert Sabin, University of Cincinnati; Dr. Edward D. Shaw, University of California School of Medicine; and Dr. Joseph E. Smadel, Public Health Service, National Institutes of Health Service, Md.

The report of the Committee's findings and recommendations is attached.

4011

B. <u>Report of the Special Advisory Committee on Oral Poliomyelitis</u> Vaccine to the Surgeon General, PHS. December 18, 1962

The Committee met to review all cases of suspect polio-like illness currently known to have been associated with the administration of oral poliovirus vaccine of all three types in non-epidemic areas. These included, in addition to cases previously considered, 25 cases newly discovered among persons fed vaccine and four cases among individuals in contact with vaccinated persons. Some of the cases previously accepted as "compatible" have been dropped from this category because of additional clinical and laboratory evidence that has become available. New cases have been added to the "compatible" group where careful review has justified such action.

Cases Considered by the Special

It should be emphasized that the committee does not consider that an individual case can be proved to be caused by the vaccine and no laboratory test has thus far provided a definitive answer. However, it has attempted to decide for each case whether or not it is "compatible" with the possibility of having been induced by the vaccine. Cases have been judged as "compatible" when three criteria were met: (1) onset within a period (4-30 days after feeding) consistent with a reasonable incubation period; (2) an illness clinically consistent with paralytic polio; and (3) laboratory findings which do not exclude a vaccine relationship.

On the basis of data now available the total number of cases associated in time with the direct administration of Type III vaccine and considered by a committee majority as "compatible" is now 11, of which 8 are over 30 years of age. Four cases were excluded as clearly unrelated to Type III vaccination; and seven cases were considered inconclusive as to a possible vaccine relationship. The total number of cases associated with the administration of Type I vaccine and considered as "compatible" is seven, of which 4 are over 30 years of age. Ten cases were excluded; six were considered inconclusive. None of the three Type II associated cases was judged to be "compatible".

It should be noted that the total number of doses of oral vaccine given in non-epidemic areas during 1962 is approximately 31 million Type I, 19 million Type II and 15 million Type III. Hence, the maximum potential risk for Types I and III is of the order of one per million or less overall, but higher for those over 30 years of age. For Type II there is still no indication of risk.

Consideration of the four cases in unvaccinated persons in household contact with vaccinees resulted in two being judged "compatible" and two "excluded". One additional "compatible" case occurred in a nonhousehold contact. Considering the large amount of vaccine administered and the known frequency of vaccine virus spread from vaccinated to unvaccinated persons, particularly within homes, it is concluded that contact spread has posed no significant hazard.

It is therefore recommended: (1) that community plans for immunization be encouraged, using all three types; and (2) that immunization be emphasized for children in whom the danger of naturally occurring poliomyelitis is greatest and who serve as the natural source of poliomyelitis infection in the community. Because the need for immunization diminishes with advancing age and because potential risks of vaccine are believed by some to exist in adults, especially above the age of 30, vaccination should be used for adults only with the full recognition of its very small risk. Vaccination is especially recommended for those adults who are at higher risk of naturally occurring disease; for example, parents of young children, pregnant women, persons in epidemic situations and those planning foreign travel.

as "comparible" have been dropped from this category because of additional c gnimono fo noncoming vaccination of oncoming generations to the "comparible" croup where case of reviewing

fied such action.

C. Cases Considered by the Special Advisory Committee

As stated in the report of the Advisory Committee, all known cases of suspect polio-like illness associated in time with the administration of the three types of oral polio vaccines outside of epidemic areas were reviewed. The line listings which appear below categorize the cases for consideration as occurring after the administration of Type I, Type II or Type III vaccine. Thus any case with onset more than 30 days after one type of vaccine administration but within 30 days of a second type received 2 reviews. Two cases, as indicated in the listing, were considered both as primary vaccinees and as contacts of vaccinees.

All cases considered have been listed in previous P.S.U. reports except for ten cases from California which have not yet been officially reported. These were considered from a special report prepared and submitted to the Committee by the California State Department of Public Health. The Committee appraisal on each individual case is indicated, based on the criteria listed in their report. Cases of Polio-like Illness Following Oral Polio Vaccines Occurring Outside of Epidemic Areas in 1962 - Reviewed by the Surgeon General's Advisory Committee on Poliomyelitis Vaccines

No Specimen
No Isolate Obtained
** In Process

I. Cases Following Type I Vaccine

			Doses		m Feeding of Illne		Viri	is Isolate	Antibody	Committee
State	Age	Sex	IPV	I		111	Туре	Character	Response	Appraisal
Calif.	2 8	М	4	2(7) ¹			I	**	I	Excluded
Calif.(NR)	11	М	4	? (4)			0		Inconclusive	Inconclusive
Calif.(NR)	32	М	0	(14)			I	**	I	Compatible
Calif.	42	М	0	8(11)			I	**	I	Compatible
Calif.	2	F	2	18(19)			I	**	I	Compatible
Calif.	58	М	0	25(26)			**		Inconclusive	Compatible ³
Calif.(NR)	3	М	5	?(40)			I	**	**	Excluded
Calif.	7	F	6	22(25)			11 ⁵	**	Inconclusive	Inconclusive
Calif.(NR)	33	М	3	-2(12)			III	**	Inconclusive	Excluded
Calif.(NR)	30	М	3	14(23)			III	**	Inconclusive	Excluded
Calif.(NR)	4	F	?	-4(8)			I	**	Inconclusive	Excluded
Calif.(NR)	11	М	4	-8(6)			I	**	Inconclusive	Excluded
Calif.(NR)	33	М	0	9(18)			0		**	Inconclusive
Calif.(NR)	37	М	8	(97)	1	48	-		-	Excluded
Calif.(NR)	35	М	0	9(11)			I	**	**	Compatible
I11.	16	М	?	4(6)			I	Non-Vacc.like	: I	Compatible
								(3 Specimens		
								Vaccine-like		
								(1 Specimen)		
Iowa	14	F	3	(9)			I	Vaccine-like	I, II	Compatible
Mass.	7	М	5	(27)			I	Vaccine-like	Inconclusive	Excluded
Mass.	11	M	4	16(30)			-	taberne rike		Inconclusive
										Inconcrusive

anvieor desensi,s Vquispud Comuttee ou BollowAsjirys Ascorces Occanitis Daterge of Sbigemic Less in 1827 - Daalawey P the Cores of Bollo-Jike Tijvers gajjawing Diej Mayar Ascurac

ar le protese O to Isoface Opfarato - Ko fictore

1. Cases Following Type I Vactus

Lucon tratis Real aged	Country 27 076 Country 27 076	Excreted Treater	Exc Luded	gao ludeo Exeludeo	Turourfrey. Budfreed	Could starter	route states and the second states of the second st	Comine to Te	Tuscosc <i>ja</i> etae Pxcjrigeg	VB51.4.7287 VB51.4.7287
TL T TL T	1-1 - 1 1-1 1-1		Tuccucjacias Isconcjacias	Toour retains	ູ່ ມີເວັນແຮງເຊີ່ມຕໍ່ ແຜ	Inconclustve	nt (proj))	Seend	Tu conciuaição I	gunt pack
Ascerne-Tree Ascerne-Tree Ascerne-Tree Ascerne-Tree Ascerne-Tree	1.100 - 1.000 - 1.100		14 14 14 14 14 14 14 14 14 14 14 14 14 1	· · · · · · · · · · · · · · · · · · ·	* *			Series.	5. 27	STALASI - 8
n der ber	ing pag	1.0	to ng fanas	and and been for	571	1.2		in s	o A	JA53 ATT 78
										II IIIIIess III Losques 01.01
160) (0) (0)	4 (2) 3 (13)	(SZ) 5 (22)	-2(2)	TV(53) -5(15)	55(22) 5(00)	32(Se) 20(Se)	in front	(ΔE)	5 (3) 5 (3)	L Lo Alteor Dala Licu
5 N M	~ 0		t	en m	e n	01	5 O	0	5 1	Doses
2 2 4	13 E	ing 124	Z 141		ні (З	2	a II.		kas. Istory - Star	16 16
H 7 5	0 ľ.	a n n	the to	000	10	n es t Na	0 10 10	613 (11)	50	
	(1937) .	(310). (310).	t (38) t (38)	(301).1 (301).1	ξ'' τ'(ΝΤΓ)	, , , , t _i , ,	1	(NY).1	(3E).1	10
N 89 85 N 89 85 N 97 95 N 96 N 96 N 96 N 96 N 96 N 96 N 96 N 96	14 17 17 17 17 17 17 17 17 17 17 17 17 17	lan lange ban lange	Series June	1180	LISO Call	1180		CRC 1	Call in the	67536

							-	• No Specimen		
I. <u>Cases</u>	Follow	ing T	ype I V	accine (Continued)		C) No Isolate (Obtained	
							**	In Process		
				Days fr	om Feeding	of OPV				
			Doses	to Onse	t of Illne	ss ¹	Viru	is Isolate	Antibody	Committee
State	Age	Sex	IPV	_ <u>I_</u>	11	III	Type	Character	Response	Appraisal
	-								_	
N.Y.(1) ⁴	3	М	2	(23)			I	Non-Vacc.Like	I	Excluded
Ohio	16	М	0	28(43)		1(15)	-		III	Inconclusive
Tenn.(2)	25	М	1	4(11)			I	Non-Vacc.Like	I, II, III	Inconclusive
Wash.6	6	М	4	(37)		(5)	I	Vaccine-Like	I	Excluded

1. The number in parenthesis indicates interval from feeding to onset of paralysis.

- 2. (NR) California cases not yet officially reported but considered from a special report submitted by the California State Department of Public Health.
- 3. Considered a "compatible" case if laboratory work in process is not inconsistent with a vaccine relationship.
- 4. Number in parenthesis following State designation corresponds with the number of the case in the technical report of the Surgeon General September 20, 1962.
- 5. Specimen taken two days after patient received Type II vaccine.
- 6. Also considered (and listed) with relation to Type III vaccine.

<i>i</i>		Municar M		terther.	action of	rears set	the South	iaco grossing da dell'eróp	ol er sekrite beretik en inveriert reudel og tit gannenn (norsef) - genereden (for 160) Humber is barentigerig jojjosini joste tregjuvergon tallordonje sign sjer sunpru	1003 Prix
*	ŝ	Содаі (Пора	Coustered &	artp . comist	Ascrite Etplo ₁ cs:	gucoustarest atth - Ascrine referrouspip. Consignred a pompatific frae tighterestry.	t5.' Xspor≥ zo	ψεμ – Ascrywa πεγησγουεργύγ combagaga, chas γεγεύματουλ κοίκ το δτοκγια γα αας	is in the c	
	20		rubeur enpantres (MEV) California	ដែនខេត្ត ២ភិ ស្រុក ខ្លួនខេត្	the Call	fornth Star	as Debur p th tebo re	g på spe Cerritusers Stars Deburget pas-covrycare, gaster Sates vor kee ofrigte Stars Deburget paster of Annig Gester,		fairega a
	î. Îrre	H SAT	neper 41	a barea	ाः कडेक्द्र ह	85 c 31 68 - 20	xì Levres	galbes] wo	sizulars of o teaco of galbeel work levrene entrolleri sizedinaraq al redama adl	yàrts.
N.Y.N Ohio Tenn.(2) Salah S	0 12 0 M	7 7 7 7 R	5-02	(23) 26(4	~~~~	(e) 1 (re)		sili.cosV-moM I - oili.cosY-reV · I · - pild-origory · I .		Exclused Inconclusive Inconclusive
61800	991	26%	164 Doree	T Dev	lo Salises rom Feeding I Lassill I 1 1986 I I 1 1 1986 I	VHO io Saibssa mori a Jassalli o 192200 JII			Vin 1 T pour V	Count price
1 . Case a	E o I I c	Cases follosias 1706 I	tabs I /	or to as V	Vaccine (Continued)	6 d)	34 © 1 92	en No	Bitocess Isolsta Optaland Sbearmour	

. arboner III says of raisaler offer (herebi brs) berebicuun osli. "e-

through a pupper true gails utuan heriour to sight the fiber of Abstract Ascuration

or int deservutings routider ishbair ou into candeon manatan a pebesanen ant taon .

II. <u>Cases Following Type II Vaccine</u>

No Specimen
No Isolate Obtained
** In Process

			Doses	Days fr to Onse	om Feedin t of Illne	ng of OPV ess	<u>Virus Isolate</u>	Antibody	Committee
State	Age	<u>Sex</u>	<u>IPV</u>	Ī	<u>11</u>	<u>111</u>	Type Character	Response	Appraisal
Neb	5	F	4	(>90)	16(23)	(>90)	**	Incon.	Inconclusive
Ohio(3)	2	F	2	(85)	(8)	-	III	-	Excluded
OhioI	67	М	0	(64)	(8)	(36)	0	Incon.	Inconclusive

1 Also considered and listed with relation to Type III vaccine

f attantyret Le Reotratet fucotorinte	South States	
11-1-17-1 	10000 - 10000 10000 - 100000 10000 - 1000000	
	Land Trates	a⊨ lu llocene O ko teojara nata(asa - ⊻o graojara
(20) (20) (20)	177 624 E at 014	4 G 1 9 9 9 9
6) 16(23) 76	Losop al Irras 2 Zhan Lead E al 014	a proc
64) 64) 64)	T Sol Col	10003
O K P	152	I Convi
in a pi		3.1
a ha a		and the second second
chiat chiat(3) McP	27832	. <u>Calab</u> .

school li cycl of deisler dit with termine to lyre there been set $\hat{\lambda}$

III. Cases Following Type III Vaccine

			Doses		om Feedir cof Illr	ng of OPV
State	Age	Sex	IPV	I	II	III
otate						
Mass.	4	М	4	54(64)		26(36)
Mass.	54	F	0			22(24)
Mich.(4)	23	М	2 or 4	76(80)		16(20)
						•
(-)		_	•			00(00)
Mich.(5)	36	F	0			22(28)
Neb.(6)	18	F	5	34(42)		7(15)
Neb.(7)	51	М	0	51(54)		22(25)
Neb.(8)	37	М	0	43(48)		15(20)
Neb.	50	F	4	61(69)		19(27)
Neb.	57	М	0	49(57)		12(20)
Neb.	6	М	3	49(56)		7(14)
Neb.	13	F	3	41 (44)		16(19)
Neb.	55	М	0	46(52)		10(16)
NY(9)	49	М	0	(>90)		26 (29)
Ohio ²	67	М	0	(64)	(8)	(36)
$0hio(10)^3$	16	M	Ō	28(43)		1(15)
0hio(11)4	36	М	Ō			21(25)
Oregon(12)	48	F	Õ	34(38)		7(11)
Oregon(13)	39	M	Õ	50(51)		23(24)
Oregon(14)	6	M	õ	(54)		(27)
	Ū	••	Ũ	(34)		(21)
() magazy (] 5)	50		•			
O re gon(15) Penna.	52	M	0	52(53)		19(20)
	6	M	5	(55)		(8)
Wash.(16) ³	6	М	4	(37)		(5)
1 Type II v	accine	fer	1 8 dave	hafora	noniman	

1 Type II vaccine fed 8 days before specimen collected 2 Also considered (and listed) with relation to Type II 3 Also considered (and listed) with relation to Type I 4 Also compatible with Type I household contact spread - No Specimen O No Isolate Obtained ** In Process

Virus Type	and the second se	Antibody Response	Conmittee Appraisal
0 0 111	Intermediate to non-vaccin	- ** Inccn.	Excluded Inconclusive Compatible
111	like Vaccine-like	III	Compatible
111 0	Vaccine-like	Incon. Incon.	Compatible Compatible
-0		Incon. I, II, III	Compatible Compatible
0 III		I Incon.	Inconclusive Inconclusive
111	Vaccine-like	Incon. Incon.	Compatible Inconclusive
0		I, II, III Incon.	Inconclusive
-		III	Inconclusive
0 111	Vaccine-like	I, III I, II, III	Compatible Compatible
III I	Vaccine-like Non-vaccine	Incon. Incon.	Compatible Excluded
111	like Vaccine–like		
III III	Vaccine-like Vaccine-like	Incon. Incon.	Compatible Excluded
I	Vaccine-like	I	Excluded

vaccine vaccine

T LUC II A	vaccine	502 6	5 3 878	perer	sosoimen call ested				
100	0	147	\$	うちょうで	(3)		Escoute-Jaxe	ş	
Š,) c	< 12	r a		- <u>()</u>	1.2.1	Vaccina-Trke	1,150.030 *	5 4 4 4 5 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
penua Di ARANITO I	v v a	5 5	# C	53 (53) 53	10(20)	111	Vscorne-]ike	TTCOB*	1000 at 733 a
11 11	5	ç.		5		in and the second se	SHLL-SE COOS?		
							119:00		
Sector (14)	φ	24	o	1. col		21	정수의 그 방수는 이제를	110100 L	
0teso (1)	in M	24	0	Same	531743			A LTUNEL	a Ed En un read
Oregon(IS)	00 25	14		그 한 (38)	1(1)7		Vaccine-like	LI TI LI	
OPES (TT) A		14	0		S2 (3.57)	¢			0.00 g a trà 5 2 0.00
$0 \mu ro (TO)_{2}$	9		0			1			recoucynaries
OFTON	64	M	0		(36)	0		3.100012 e	j montaj naj z c
(e) YN	(C) 7		0	(90)	36(50)	ੇ		T' II' II'	Theoster astad
Kep.	čų Ci	K	0		(35)0	,r			L.coucymayae
. doği	C.	al l	(*)		Te (Ta)		Sector as - 1 - 1 &	181.03.4	Comparings
:40D *	¢,	1	ço			14		. 110.011	THE INCLUSION STATE
, debi	T _{cu}	P.	0	(うび)のヤ	(00)25	°		ja.e.	THEOROFIEST AG
	¢2	ь.i	-gr		JB(34)	Ċ		st II .	Contra Price 4
Nep*(8)	$\nabla \Sigma$	8.0° 1 ^{° 1} 1	0		FE (50)				gomhs crist 6
- 5	1.1		0		32(32)	¢		Incon.	Cumberry pro
1000	30 27		cu			frank jame	Vacuus-1176	, 110 - 11 L	COLTOR CT D1 6
ingert 14 26	36	1	0		22(28)	feerig haad jaard	V.socina-11/re	TI	Gowfreezere
							1.1 K.6		
- 19	0						40 -100-7800110		
2.10	50	ī,	2 2 2 2	04 (22) AU		-	i stratistica og og and	LINCE .	CONTROL 6 10 10 10
N N N	11 12	வி	0		11200	Ó]aconclosive.
	17		24	(4-0) * C	3P(34)	Ç		ŝ	19111773
57340	9.05	3eX	15A 10362	to guideof mori sysu rasuffi to teaso or Li II II II I I	TT Dese UE of dis	12.02	jauna na Taofo <i>n</i>	VILL FORSO	Courteat Transfert
agest .III		2117 L (17	Loffostik Link 4	T ANCESSES			<pre>c> IP Dransas 0 Hr Trojute 0 Hr Trojute</pre>	ປະດາຊອຣ ໃຫ້ບາງສະຄຸດການການ ຊີມີຄະມານກາ	

Allac compatible with Type I benevial apactment of Type I whoch a days between a type I whoch a days benevial with the contract a type I who contrect a type I who contract a type I who contract a

Cases Among Household Contacts of Vaccinees

<u>State</u>	Age	<u>Sex</u>	Doses IPV		rom Feedi et of Ill <u>II</u>	ing of OPV Iness <u>111</u>
La. Mass. Mass.	21 42 18/12	M F M	0 4 0	(55) (59)		(26) (25) (18)
NY Ohio ^l	29 6/12	M M	0 0	(55) (69)		(25) (33)

1 Contact in adjacent apartment

-	No	Specim	en

0 No Isolate Obtained

*** In Process

Viras	<u>Tsolate</u>	Antibody	Committee
Type	Character	Response	<u>Appraisal</u>
I	**	I	Excluded
-		-	Excluded
I	Intermediate to non-vaccionate	I	Compatible
111	Vaccine-like	111	Compatible
111	Vaccine-like	-	Compatible

l fourner in adjacent aparent.	නිර්ධින හැදි අ	1852)	117*8 <i>0</i> 8	100 M T				
orroj M	evit so	teris 1997 - 1997 1997 - 1998	00		(25) (33)		Acrosise-Jike - .rodise-jiks Iri Jike	ganter a s'ho ganter a s'ho
. 222. 122. 122.	15/33 43 33	$\mathbb{Z} \neq \mathbb{Z}$	0 % 0	(53) (53)	999 899 899 899	i-4 1 -4	Luteration of the second s	Confection) National Entrancional
ST CA	os A	Track	11-242	TO SULVERS OF THE SUL	jucki mekat	TA DAR	Altur Erojate Werlesse	Louis al os
	આદે દિલ્લાક લે	1010	1. 1	on prove proveding a provision of proceedinges	992	440) 1	же 19 Длосеан О 190 Твојите селицики - 190 21-бојшен	

• • •



